Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The KALA BIO, Inc. (NASDAQ: KALA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into KALA’s clinical-stage biopharmaceutical business focused on rare and severe eye diseases, its mesenchymal stem cell secretome (MSC-S) platform, and its evolving financial and strategic position.
Through KALA’s annual reports on Form 10-K and quarterly reports on Form 10-Q, investors can review information on research and development activities, pipeline programs such as KPI-012 and KPI-014, risk factors, liquidity and capital resources. Current Reports on Form 8-K highlight material events, including the CHASE Phase 2b trial results for KPI-012, decisions to cease development of KPI-012 and the MSC-S platform, workforce reductions, financing agreements, loan defaults and settlements with Oxford Finance LLC, and Nasdaq listing deficiency notices.
KALA’s filings also include transaction-related documents, such as the Securities Purchase Agreement for Series AA and Series AAA convertible preferred stock, the Convertible Loan Agreement with an investor, and the Oxford Loan Settlement Agreement. These records explain how the company has structured recent financings, addressed debt obligations and framed its exploration of strategic alternatives. Notifications like Form 12b-25 describe timing of periodic reports when delays occur.
On Stock Titan, KALA filings are updated in near real time as they appear on EDGAR. AI-powered summaries help interpret lengthy 10-K and 10-Q reports, breaking down key sections on clinical programs, cash runway, going-concern language and risk disclosures. For Form 4 and other insider-related filings, users can quickly see reported insider transactions in KALA stock. This combination of raw filings and AI-generated explanations allows readers to understand what each document means for KALA’s business, capital structure and potential strategic direction without having to parse every page manually.
KALA BIO director Brendan P. Purdy filed an initial ownership report stating he currently holds no company securities. The Form 3 identifies him as a director of KALA BIO, Inc. and confirms that no non-derivative or derivative securities are beneficially owned as of the reported event date.
The filing also notes that a power of attorney authorizes Avraham Minkowitz to sign and submit the report on Purdy’s behalf.
KALA BIO, Inc. director Hillel D. Posen filed an initial statement of beneficial ownership as a reporting person. The filing states that no securities of KALA BIO are beneficially owned. It also records that Posen granted a power of attorney authorizing Avraham Minkowitz to sign and file the report on his behalf.
KALA BIO, Inc. filed an initial ownership report (Form 3) for Avraham Minkowitz, who is both a director and the Chief Executive Officer. As of the event date of 01/30/2026, the filing states that no securities are beneficially owned, including no derivative securities positions.
KALA BIO director reports no stock ownership in initial filing
Director Colman Yonatan C. filed an initial ownership report with KALA BIO, Inc. stating that no securities are beneficially owned. The form also notes that a Power of Attorney authorizes Avraham Minkowitz to sign and submit the filing on the director’s behalf.
KALA BIO, Inc. director Chaim D. Berger filed an initial insider ownership report on Form 3. The filing states that, as of the event date of 01/30/2026, he beneficially owns no securities of KALA BIO. The form was signed and submitted by attorney-in-fact Avraham Minkowitz under a power of attorney attached as Exhibit 24.
David E. Lazar has filed a Schedule 13D reporting a 5.18% beneficial ownership stake in KALA BIO, Inc., tied to preferred stock that is convertible into 49,500,000 shares of common stock. This stake is based on 954,749,725 shares outstanding as of February 6, 2026.
Lazar acquired 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock for $1.8 million, which became convertible into 49.5 million common shares after stockholder approval at a special meeting. The Series AA Preferred Stock includes full ratchet protection in subsequent offerings and may be assigned or transferred subject to conditions in the securities purchase agreement.
Under that agreement, Lazar was appointed Chief Executive Officer and a director effective November 23, 2025, with the right to recommend up to eight director nominees for stockholder election and to serve as Chairman upon his election. On February 2, 2026, he resigned as Chief Executive Officer but remains on the Board of Directors.
KALA BIO, Inc. reported a leadership change effective February 2, 2026. David Lazar resigned as both Chief Executive Officer and Chief Financial Officer on that date but remains a member of the board of directors.
To fill these roles, the board appointed existing director Avi Minkowitz as the new Chief Executive Officer and Chief Financial Officer, effective the same day. The company highlights his background in investment, mergers and acquisitions, real estate, and management consulting, as well as prior board and entrepreneurial experience. The filing notes there are no disclosable family relationships or related-party transactions involving Mr. Minkowitz under the cited SEC regulations.
KALA BIO, INC. closed the second part of a private preferred stock financing and reshaped its governance structure. The company sold 2,100,000 shares of Series AAA preferred stock at $2.00 per share for gross proceeds of $4.2 million, with each share convertible into 420 common shares, or 882,000,000 common shares in total. This follows a prior sale of 900,000 Series AA preferred shares for $1.8 million, convertible into 49,500,000 common shares. Stockholders approved issuing common shares upon conversion of both series, authorized increasing common stock to 1,500,000,000 shares, and approved a potential reverse split at a ratio between 1‑for‑2 and 1‑for‑100. Six incumbent directors resigned tied to these approvals, and five nominees associated with AK Holdings were appointed to the board, resulting in a significant change in board composition and control.
KALA BIO, Inc. reported that it received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement of $1.00 per share. The deficiency is based on the closing bid price for the 30 consecutive business days from December 3, 2025 to January 16, 2026.
The company has a 180-day compliance period, until July 20, 2026, for its stock to close at or above $1.00 for at least ten consecutive business days to regain compliance. If it satisfies other Nasdaq initial listing standards, it may qualify for an additional 180-day period, potentially using a reverse stock split to cure the deficiency.
The notice does not immediately affect the listing or trading of KALA’s common stock, but failure to regain compliance could lead to delisting, subject to potential appeal.
LifeSci Capital LLC reported beneficial ownership of 2,200,000 shares of KALA BIO, Inc. common stock, representing 7.9% of the outstanding class. The percentage is based on 27,849,725 shares of common stock outstanding as of December 31, 2025, as referenced from a company prospectus.
LifeSci Capital has sole voting and dispositive power over these shares. Andrew McDonald and Michael Rice are listed as reporting persons with shared voting and dispositive power over the same 2,200,000 shares through LifeSci Capital, but each disclaims beneficial ownership except for any pecuniary interest. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of KALA BIO.